Long-Term Sulfonylurea Use and Impaired Awareness of Hypoglycemia Among Patients With Type 2 Diabetes in Taiwan

被引:0
|
作者
Cheng, Hsiang-Ju [1 ]
Weng, Siou-Huei [2 ,3 ]
Wu, Jia-Ling [2 ]
Yeh, Shu-Tin [4 ]
Chen, Hua-Fen [4 ,5 ,6 ]
Novida, Hermina [7 ]
Ou, Huang-Tz [8 ,9 ,10 ]
Li, Chung-Yi [2 ,11 ,12 ]
机构
[1] Natl Cheng Kung Univ, Natl Cheng Kung Univ Hosp, Coll Med, Dept Family Med, Tainan, Taiwan
[2] Natl Cheng Kung Univ, Coll Med, Dept Publ Hlth, 1 Univ Rd, Tainan 701, Taiwan
[3] Tainan City Govt, Publ Hlth Bur, Dis Control Sect Div, Tainan, Taiwan
[4] Far Eastern Mem Hosp, Dept Endocrinol, New Taipei City, Taiwan
[5] Fu Jen Catholic Univ, Coll Med, Dept Med, New Taipei City, Taiwan
[6] Fu Jen Catholic Univ, Coll Med, Dept Publ Hlth, New Taipei City, Taiwan
[7] Univ Airlangga, Fac Med, Dept Internal Med, Div Endocrine Metab & Diabet, Surabaya, Indonesia
[8] Natl Cheng Kung Univ, Inst Clin Pharm & Pharmaceut Sci, Coll Med, Tainan, Taiwan
[9] Natl Cheng Kung Univ, Coll Med, Dept Pharm, Tainan, Taiwan
[10] Natl Cheng Kung Univ Hosp, Dept Pharm, Tainan, Taiwan
[11] China Med Univ, Coll Publ Hlth, Dept Publ Hlth, Taichung, Taiwan
[12] Asia Univ, Coll Med & Hlth Sci, Dept Healthcare Adm, Taichung, Taiwan
关键词
hypoglycemia; type; 2; diabetes; sulfonylurea; insulin; hypoglycemic agents; glycemic control; risk factors; diabetes complications; primary care; MECHANISMS; FREQUENCY;
D O I
10.1370/afm.3129
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
PURPOSE We undertook a study to investigate the relationship between duration of medication use and prevalence of impaired awareness of hypoglycemia (IAH) among patients with insulin-treated or sulfonylurea-treated type 2 diabetes in Taiwan. METHODS A total of 898 patients (41.0% insulin users, 65.1% sulfonylurea users; mean [SD] age = 59.9 [12.3] years, 50.7% female) were enrolled in pharmacies, clinics, and health bureaus of Tainan City, Taiwan. Presence of IAH was determined with Chinese versions of the Gold questionnaire (Gold-TW) and Clarke questionnaire (Clarke-TW). Sociodemographics, disease and treatment histories, diabetes-related medical care, and health status were collected. We used multiple logistic regression models to assess the relationship between duration of medication use and IAH. RESULTS Overall IAH prevalence was 41.0% (Gold-TW) and 28.2% (Clarke-TW) among insulin users, and 65.3% (Gold-TW) and 51.3% (Clarke-TW) among sulfonylurea users. Prevalence increased with the duration of sulfonylurea use, whereas it decreased with the duration of insulin use. After controlling for potential confounders, 5 or more years of sulfonylurea use was significantly associated with 3.50-fold (95% CI, 2.39-5.13) and 3.06-fold (95% CI, 2.114.44) increases in the odds of IAH based on the Gold-TW and Clarke-TW criteria, respectively. On the other hand, regular blood glucose testing and retinal examinations were associated with reduced odds in both insulin users and sulfonylurea users. CONCLUSIONS The prevalence of IAH was high among patients using sulfonylureas long term, but the odds of this complication were attenuated for those who received regular diabetes-related medical care. Our study suggests that long-term sulfonylurea use and irregular follow-up increase risk for IAH. Further prospective studies are needed to confirm the observed associations. Ann Fam Med 2024;22:309-316. https://doi.org/10.1370/afm.3129 Annals Early Access article
引用
收藏
页码:309 / 316
页数:8
相关论文
共 50 条
  • [31] Long-term improvement of metabolic control by acarbose in type 2 diabetes patients poorly controlled with maximum sulfonylurea therapy
    Bachmann, W
    Petzinna, D
    Raptis, SA
    Wascher, T
    Westermeier, T
    CLINICAL DRUG INVESTIGATION, 2003, 23 (10) : 679 - 686
  • [32] Long-Term Improvement of Metabolic Control by Acarbose in Type 2 Diabetes Patients Poorly Controlled with Maximum Sulfonylurea Therapy
    Werner Bachmann
    Dieter Petzinna
    Sotirios A. Raptis
    Thomas Wascher
    Torsten Westermeier
    Clinical Drug Investigation, 2003, 23 : 679 - 686
  • [33] Long-term exposure to NO2 and PM2.5 and the occurrence of chronic kidney disease among patients with type 2 diabetes in Taiwan
    Chin, Wei-Shan
    Guo, Yue-Liang Leon
    Chang, Yu-Kang
    Huang, Li-Feng
    Hsu, Chih-Cheng
    ECOTOXICOLOGY AND ENVIRONMENTAL SAFETY, 2024, 284
  • [34] Association of impaired awareness of hypoglycemia and changes in the brain Type 1 diabetes
    Jecht, Michael
    DIABETOLOGE, 2020, 16 (01): : 79 - 80
  • [35] An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes
    Wright, Rohana J.
    Geddes, Jacqueline
    Zammitt, Nicola N.
    Deary, Ian J.
    Frier, Brian M.
    DIABETES, 2007, 56 : A44 - A44
  • [36] Impact of Hybrid Closed Loop Therapy on Hypoglycemia Awareness in Individuals with Type 1 Diabetes and Impaired Hypoglycemia Awareness
    Burckhardt, Marie-Anne
    Abraham, Mary B.
    Dart, Julie
    Smith, Grant J.
    Paramalingam, Nirubasini
    O'Dea, Joanne
    de Bock, Martin
    Davis, Elizabeth A.
    Jones, Timothy W.
    DIABETES TECHNOLOGY & THERAPEUTICS, 2021, 23 (07) : 482 - 490
  • [37] Reduction of Sulfonylurea with the Initiation of Basal Insulin in Patients with Inadequately Controlled Type 2 Diabetes Mellitus Undergoing Long-Term Sulfonylurea-Based Treatment
    Yang, Yeoree
    Shin, Jeong-Ah
    Yang, Hae Kyung
    Lee, Seung-Hwan
    Ko, Seung-Hyun
    Ahn, Yu-Bae
    Yoon, Kun-Ho
    Cho, Jae-Hyoung
    DIABETES & METABOLISM JOURNAL, 2016, 40 (06) : 454 - 462
  • [38] An evaluation of methods of assessing impaired awareness of hypoglycemia in type 1 diabetes
    Geddes, Jacqueline
    Wright, Rohana J.
    Zammitt, Nicola N.
    Deary, Ian J.
    Frier, Brian M.
    DIABETES CARE, 2007, 30 (07) : 1868 - 1870
  • [39] The decision not to drive during hypoglycemia in patients with type 1 and type 2 diabetes, according to hypoglycemia awareness
    Stork, Alexander D.
    Van Haeften, Timon W.
    Veneman, Thiemo F.
    DIABETES, 2007, 56 : A44 - A44
  • [40] Pharmacogenetics of sulfonylurea-induced hypoglycemia in Type 2 diabetes patients: the SUCLINGEN study
    Loganadan, Navin Kumar
    Huri, Hasniza Zaman
    Vethakkan, Shireene Ratna
    Hussein, Zanariah
    PHARMACOGENOMICS, 2021, 22 (16) : 1057 - 1068